Abstract
Linda Jones was a healthy, 35-year-old lawyer who was pregnant for the second time. Her first child was a healthy, now 10-year-old girl. At Linda’s initial prenatal visit she discussed fragile X testing with her physician, having read about it in a popular magazine. Although Linda’s first child did not have fragile X syndrome and there was no history of mental retardation or autism-spectrum disorders in her family, she requested carrier screening for fragile X syndrome.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Jacquemont S, Hagerman RJ, Hagerman PJ et al (2007) Fragile-X syndrome and fragile X-associated tremor/ataxia syndrome: two faces of FMR1. Lancet Neurol 6:45–55
Wells RD (2009) Mutation spectra in fragile X syndrome induced by deletions of CGG?CCG repeats. J Biol Chem 284:7407–7411
Nolin SL, Brown TW, Glicksman A et al (2003) Expansion of the fragile X CGG repeat in females with premutation or intermediate alleles. Am J Hum Genet 72:454–464
Dölen G, Osterweil E, Rao S et al (2007) Correction of fragile X syndrome in mice. Neuron 56:955–962
Dölen G, Bear M (2008) Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome. J Physiol 586:1503–1508
Kuehn BM (2009) Fragile X therapy probed. JAMA 302:2644
Sherman S, Pletcher BA, Driscol DA (2005) Fragile X syndrome: diagnostic and carrier testing. Genet Med 7:584–587
McConkie-Rosell A, Finucan B, Cronister A et al (2005) Genetic counseling for fragile X syndrome: updated recommendations of the national society of genetic counselors. J Genet Couns 14:249–270
Cronister A, DiMaio M, Mahoney MJ et al (2005) Fragile X syndrome carrier screening in the prenatal genetic counseling setting. Genet Med 7:246–250
Hill MK, Archibald AD, Cohen J et al (2010) A systematic review of population screening for fragile X syndrome. Genet Med 12:396–410
Daly TM, Rafii A, Martin RA et al (2000) Novel polymorphism in the FMR1 gene results in a “pseudodeletion” of FMR1 in a commonly used fragile X assay. J Mol Diagn 2:128–131
Coffee B, Ikeda M, Budimirovic DB et al (2008) Mosaic FMR1 deletion causes fragile X syndrome and can lead to molecular misdiagnosis: a case report and review of the literature. Am J Med Genet A 146A:1358–1367
Schrijver I, Cherny SC, Zehnder JL (2007) Testing for maternal cell contamination in prenatal samples. J Mol Diagn 9:394–400
Recommended Reading
Maddelena A, Richards CS (2001) Technical standards and guidelines for fragile X. Genet Med 3:200–205 Nagan N, Faulkner NE, Curtis C et al (2011) Laboratory Guidelines for Detection, Interpretation and Reporting of Maternal Cell Contamination (MCC) in Prenatal Analyses: A Report of the Association for Molecular Pathology. J Mol Diagn 13:7–11
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Heim, R.A. (2011). Fragile X Syndrome. In: Schrijver, I. (eds) Diagnostic Molecular Pathology in Practice. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-19677-5_7
Download citation
DOI: https://doi.org/10.1007/978-3-642-19677-5_7
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-19676-8
Online ISBN: 978-3-642-19677-5
eBook Packages: MedicineMedicine (R0)